Analysts Set Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Price Target at $69.46

Shares of Rhythm Pharmaceuticals, Inc. ( NASDAQ:RYTM – Get Free Report ) have received a consensus rating of “Moderate Buy” from the thirteen ratings firms that are presently covering the company, Marketbeat.com reports.

One research analyst has rated the stock with a hold rating and twelve have issued a buy rating on the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $69.46.



Several brokerages have issued reports on RYTM. Oppenheimer initiated coverage on shares of Rhythm Pharmaceuticals in a research note on Friday, December 20th. They set an “outperform” rating and a $76.

00 target price on the stock. Stifel Nicolaus began coverage on shares of Rhythm Pharmaceuticals in a research report on Wednesday, March 5th. They issued a “buy” rating and a $78.

00 price target for the company. HC Wainwright reissued a “buy” rating and set a $70.00 price objective on shares of Rhythm Pharmaceuticals in a research report on Monday, March 24th.

JMP Securities reaffirmed a “market outperform” rating and issued a $75.00 target price on shares of Rhythm Pharmaceuticals in a research report on Monday, December 23rd. Finally, Jefferies Financial Group initiated coverage on Rhythm Pharmaceuticals in a report on Thursday, January 2nd.

They set a “buy” rating and a $80.00 price target for the company. Get Our Latest Report on Rhythm Pharmaceuticals Insider Activity Institutional Trading of Rhythm Pharmaceuticals Institutional investors have recently modified their holdings of the company.

FMR LLC lifted its position in Rhythm Pharmaceuticals by 79.7% in the third quarter. FMR LLC now owns 50,295 shares of the company’s stock worth $2,635,000 after purchasing an additional 22,306 shares during the period.

BNP Paribas Financial Markets boosted its position in shares of Rhythm Pharmaceuticals by 307.1% during the 3rd quarter. BNP Paribas Financial Markets now owns 14,425 shares of the company’s stock valued at $756,000 after acquiring an additional 10,882 shares in the last quarter.

Principal Financial Group Inc. increased its stake in Rhythm Pharmaceuticals by 241.9% in the third quarter.

Principal Financial Group Inc. now owns 32,586 shares of the company’s stock valued at $1,707,000 after acquiring an additional 23,054 shares during the period. Intech Investment Management LLC acquired a new position in Rhythm Pharmaceuticals in the third quarter worth about $649,000.

Finally, Charles Schwab Investment Management Inc. boosted its holdings in Rhythm Pharmaceuticals by 1.4% during the third quarter.

Charles Schwab Investment Management Inc. now owns 433,866 shares of the company’s stock valued at $22,730,000 after purchasing an additional 5,908 shares in the last quarter. Rhythm Pharmaceuticals Stock Up 3.

9 % Shares of Rhythm Pharmaceuticals stock opened at $51.96 on Friday. Rhythm Pharmaceuticals has a 12-month low of $35.

17 and a 12-month high of $68.58. The firm has a market capitalization of $3.

29 billion, a PE ratio of -12.00 and a beta of 2.30.

The stock’s fifty day moving average is $54.96 and its 200-day moving average is $55.12.

Rhythm Pharmaceuticals ( NASDAQ:RYTM – Get Free Report ) last posted its quarterly earnings data on Wednesday, February 26th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.

69) by ($0.03). Rhythm Pharmaceuticals had a negative return on equity of 367.

36% and a negative net margin of 230.07%. The company had revenue of $41.

83 million for the quarter, compared to analyst estimates of $38.48 million. Analysts expect that Rhythm Pharmaceuticals will post -4.

32 EPS for the current year. About Rhythm Pharmaceuticals ( Get Free Report Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.

Read More Receive News & Ratings for Rhythm Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhythm Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter ..